Ongoing Clinical Studies in Bladder Cancer

Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.

TRIAL TITLE

TRIAL NUMBER
STAGE
STATUS
PUBLICATION

BOND-002

Safety and Efficacy

NCT02365818

Phase 2, US only

Completed

Phase 2 publication interim results

BOND-003

Phase 3

NCT04452591

Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)

Recruiting

Phase 2 publication interim results

CORE-001

Phase 2, CG0070 Combined With Pembrolizumab

NCT04387461

Phase 2, Global (US, South Korea)

Active, Not Recruiting

Phase 2 interim data (ASCO 2022)

CORE-002

Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC

NCT04610671

Phase 1b/2, US Only

Recruiting

Phase 1b/2 interim data (ASCO 2022):

Patients and Urologists interested in participating should contact:

JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.

Expanded Patient Access

How Patients can Access the on-going Studies

CG Oncology is currently focused on conducting clinical research that evaluates the safety and effectiveness of investigational cretostimogene grenadenorepvec (CG0070) in Non-Muscle Invasive Bladder Cancer (NMIBC). Our clinical trials program is the primary way for interested patients to access cretostimogene grenadenorepvec at this time. We encourage patients to speak with their healthcare providers about participating in a clinical trial and may also find information on our current clinical studies on on-going clinical trials

As a general policy, CG Oncology does not anticipate providing investigational medicines to patients until our clinical data suggests that the therapy has provided evidence of safety and efficacy as defined by the U.S. Food and Drug Administration. As a result, CG Oncology believes the most appropriate way to access our investigational therapy is through participating in one of our clinical trials.

Partners

CG Oncology is eager to partner with companies who share our passion for improving patients and their loved one’s lives. Collaborations could be in R&D, business development or clinical trials. Our partners include:

  • Merck
  • Bristol Myers Squibb
  • Roche
  • Kissei Pharmaceutical Co.
  • LEPU Medical Holdings
  • FUJIFILM Diosynth Biotechnologies

If you are interested in becoming a partner with us, please contact us at bd@cgoncology.com